Farxiga dosage for diabetes and heart failure depends on why dapagliflozin is being used and on kidney function. For many adults, dosing is once daily. Type 2 diabetes often starts at 5 mg once daily and may increase to 10 mg, while heart failure and chronic kidney disease commonly center on 10 mg once daily. The key is not just the number. Clinicians also check estimated glomerular filtration rate (eGFR), fluid status, other medicines, and infection risk before deciding whether the dose is appropriate.
This page focuses on adult use. Pediatric dosing, pregnancy, dialysis, and complex kidney disease require separate clinical guidance.
Key Takeaways
- Usual schedule: Dapagliflozin is taken once daily.
- Diabetes start: Many adults begin with 5 mg daily.
- HF and CKD: Common adult regimens use 10 mg daily.
- Kidney function: eGFR affects initiation and expected glucose lowering.
- Safety review: Hydration, infection symptoms, and sick-day rules matter.
Farxiga Dosage for Diabetes and Heart Failure: Main Rules
Farxiga is the brand name for dapagliflozin, an SGLT2 inhibitor (sodium-glucose cotransporter 2 inhibitor). It works in the kidneys by reducing glucose reabsorption, which increases glucose loss in urine. The same drug may be used for different goals: lowering blood sugar, supporting heart failure care, or reducing kidney disease progression risk.
The usual adult dosing pattern is simple, but the reason for treatment changes how clinicians think about the dose.
| Clinical goal | Common adult regimen | Key dosing point |
|---|---|---|
| Type 2 diabetes glucose control | 5 mg once daily, with possible increase to 10 mg once daily | Glucose-lowering effect depends partly on kidney function. |
| Heart failure risk reduction | 10 mg once daily | Fluid status, blood pressure, and diuretic use need review. |
| Chronic kidney disease risk reduction | 10 mg once daily | Starting treatment depends on label-specific eGFR thresholds. |
| Maximum labeled adult dose | 10 mg once daily | Higher daily doses are not recommended for labeled uses. |
Do not treat the table as a personal dosing instruction. It summarizes common label-backed patterns, while your prescriber accounts for kidney function, other medicines, and current symptoms. Farxiga tablets are commonly supplied as 5 mg and 10 mg strengths. For product naming and tablet information, see Farxiga Dapagliflozin.
CanadianInsulin.com works as a prescription referral platform, not as a prescribing service.
How the Treatment Goal Changes the Dose
The same tablet may be used for different clinical goals, so the dose discussion should start with the indication. A dose chosen for blood sugar control may not be framed the same way as a dose used for heart or kidney protection.
Type 2 diabetes
For type 2 diabetes, dapagliflozin helps lower blood glucose by increasing urinary glucose excretion. Many adults start at 5 mg once daily. If additional glycemic control is needed and the medicine is tolerated, clinicians may consider 10 mg once daily. This decision often depends on A1C targets, kidney function, volume status, and other glucose-lowering medicines.
Dapagliflozin is not a replacement for individualized diabetes planning. It may be used with medicines such as metformin, GLP-1 receptor agonists, DPP-4 inhibitors, sulfonylureas, or insulin when a clinician decides the combination is appropriate. For broader condition context, the Type 2 Diabetes hub groups related educational resources. If metformin is part of the regimen, the Metformin page can help identify the medicine being discussed.
Heart failure
For heart failure, dapagliflozin dosing is usually focused on cardiovascular risk reduction rather than A1C lowering. The common adult regimen is 10 mg once daily. Clinicians often review blood pressure, kidney function, and diuretic therapy before starting, because SGLT2 inhibitors can increase urination and contribute to volume depletion in susceptible people.
This is especially relevant for people who already take loop diuretics or have low blood pressure symptoms. A prescriber may monitor dizziness, swelling, weight changes, and kidney labs after treatment begins. The dose is not usually increased above 10 mg to chase additional heart failure benefit.
Chronic kidney disease
For chronic kidney disease, the common adult regimen is also 10 mg once daily when use is appropriate. The goal is kidney and cardiovascular risk reduction, not primarily glucose lowering. This distinction matters because glucose-lowering effects weaken as kidney filtration declines, while kidney and heart indications may still be considered within label-specified eGFR ranges.
People with CKD may also take ACE inhibitors, ARBs, diuretics, mineralocorticoid receptor antagonists, or other medicines that affect blood pressure and kidney labs. That makes medication review important before and after starting dapagliflozin.
Kidney Function, eGFR, and Dose Adjustment
Kidney function does not usually create a small stepwise dose adjustment for dapagliflozin. Instead, eGFR mainly affects whether starting is appropriate, which indication applies, and how much glucose lowering to expect.
Current U.S. labeling distinguishes several eGFR ranges, including 45 mL/min/1.73 m² or higher, 25 to below 45 mL/min/1.73 m², and below 25 mL/min/1.73 m². For glycemic control alone, dapagliflozin is less useful at lower eGFR because less glucose can be filtered and excreted. For heart failure or CKD risk reduction, clinicians may use different label thresholds. It is generally not used in people receiving dialysis.
Why it matters: The same 10 mg tablet can mean different things depending on the treatment goal.
Before starting, clinicians may check serum creatinine, eGFR, and sometimes electrolytes. Follow-up labs may be repeated after initiation or after changes in diuretics, blood pressure medicines, or kidney status. A short-term dip in eGFR can occur with SGLT2 inhibitors, but ongoing monitoring helps distinguish expected changes from clinically important kidney stress.
When required, prescription details may be checked with the prescriber before referral processing.
Daily Administration and Missed-Dose Steps
Daily use is usually straightforward: dapagliflozin is taken once per day, with or without food. Many people choose morning dosing because increased urination can be easier to manage during the day. The most important habit is consistency.
Use the tablet as dispensed. Ask a pharmacist or prescriber before splitting, crushing, or changing how the tablet is taken. If a dose is missed, it is commonly taken when remembered unless it is close to the next scheduled dose. If the next dose is near, the missed dose is usually skipped. Do not take two doses at the same time to make up for a missed tablet.
Illness can change the safety picture. Vomiting, diarrhea, poor fluid intake, fever, fasting, or planned surgery may increase dehydration or ketoacidosis risk. Some clinicians provide sick-day instructions that temporarily pause SGLT2 inhibitors during high-risk situations. Follow the plan given by the treating clinician, and ask in advance if surgery or prolonged fasting is planned.
Safety, Warnings, and Interactions to Review
The main safety issues involve fluid balance, genital or urinary infections, and rare ketoacidosis. These risks are not the same for everyone. Older adults, people taking diuretics, and people with reduced kidney function may need closer monitoring for dehydration or low blood pressure.
- Genital yeast infection: itching, irritation, redness, or unusual discharge can occur.
- Urinary infection: burning, urgency, fever, or flank pain needs attention.
- Volume depletion: dizziness, faintness, or weakness can signal low fluid volume.
- Ketoacidosis: nausea, vomiting, abdominal pain, fast breathing, or confusion can occur even if glucose is not very high.
- Severe perineal infection: pain, swelling, fever, or tenderness near the genitals requires urgent care.
Dapagliflozin alone is not usually associated with frequent low blood sugar. However, hypoglycemia risk can rise when it is combined with insulin or medicines that increase insulin release, such as sulfonylureas. A prescriber may review those medicines when adding an SGLT2 inhibitor.
Drug interaction review should also include diuretics, blood pressure medicines, kidney-affecting drugs, and any medicines started recently. Alcohol intake, very low-carbohydrate eating patterns, prolonged fasting, and acute illness may also affect ketoacidosis risk. For broader diabetes regimen planning, see Acceptable Combinations of Diabetes Medications.
Quick tip: Keep a current medication list available for every diabetes or heart visit.
Comparing Related Treatment Options
If glucose targets are not met, clinicians usually do not increase dapagliflozin above the maximum labeled dose. They may instead review adherence, kidney function, diet patterns, weight goals, heart and kidney history, and the rest of the medication plan.
SGLT2 inhibitors are one class among several options for type 2 diabetes. Some people also use GLP-1 receptor agonists, DPP-4 inhibitors, basal insulin, rapid-acting insulin, or metformin-based regimens. For class-level comparisons, Invokana vs Farxiga reviews two SGLT2 inhibitors, while Rybelsus vs Jardiance compares an oral GLP-1 receptor agonist with an SGLT2 inhibitor.
Some fixed-dose tablets combine diabetes medicines to simplify regimens. For example, Synjardy combines metformin with a different SGLT2 inhibitor. These products are not interchangeable with dapagliflozin, but they show why ingredient names matter. The Diabetes Products category can be used as a browseable list when comparing medication forms and classes.
Dispensing and fulfilment, where permitted, are handled by licensed third-party pharmacies.
Questions to Prepare Before Follow-Up
A short question list can make dosing visits more useful. It also helps separate dose questions from safety and monitoring questions.
- Treatment goal: Is the main goal glucose, heart failure, CKD, or more than one?
- Kidney labs: What is the current eGFR, and when should it be rechecked?
- Fluid status: Should diuretics or blood pressure trends be reviewed?
- Infection history: What symptoms should be reported early?
- Missed doses: What plan should be followed if a tablet is forgotten?
- Sick days: Should the medicine be paused during vomiting, fasting, or surgery?
These questions do not replace medical advice. They help structure the discussion so the final plan reflects the reason for treatment and the person’s overall risk profile.
Authoritative Sources
- See the FDA drug label record for labeled indications, renal thresholds, adult dosing, and warnings.
- Review the heart failure guideline for the role of SGLT2 inhibitors in guideline-directed care.
- Read KDIGO kidney guidance for diabetes and chronic kidney disease management context.
Recap
Dapagliflozin dosing is once daily, but the clinical context matters. Type 2 diabetes may start at 5 mg once daily and increase to 10 mg when appropriate. Heart failure and chronic kidney disease regimens commonly use 10 mg once daily in adults when labeling and clinical factors support use.
The most important dosing checks are kidney function, treatment goal, fluid status, other medicines, and warning symptoms. Do not double doses, and ask for clear sick-day instructions before illness, fasting, or planned procedures.
This content is for informational purposes only and is not a substitute for professional medical advice.
